FCM
MLYS icon

Farallon Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Farallon Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-823,296
Closed -$29.9M – 191
2025
Q4 		$29.9M Sell
823,296
-849,757
-51% -$34.1M 0.14% 63
2025
Q3 		$63.4M Buy
+1,673,053
New +$36.2M 0.26% 54

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Farallon Capital Management's MLYS Position: Q1 2026 in Review

Farallon Capital Management sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 823,296 shares — an estimated $29.9M sold.

Farallon Capital Management first reported a position in MLYS in Q3 2025 and held it in 2 quarters. The position peaked at $63.4M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Farallon Capital Management reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Farallon Capital Management sold 823,296 Mineralys Therapeutics shares in Q1 2026, an estimated $29.9M.
  • Farallon Capital Management first reported a position in Mineralys Therapeutics in Q3 2025 and held it in 2 quarters.
  • Farallon Capital Management's Mineralys Therapeutics position peaked at $63.4M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.